Nuvation Set For First Launch With Ibtrozi In Lung Cancer

The US FDA approved taletrectinib for the treatment of ROS1+ NSCLC, where Nuvation hopes it will lead the category with a best-in-class position.

Key Takeaways

Nuvation is launching its first commercial drug, Ibtrozi for ROS1+ NSCLC.

Nuvation is transitioning into a commercial-stage biopharma with the launch of Ibtrozi (taletrectinib) for the treatment of ROS1-positive non-small cell...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Watch This Space: Miltenyi‘s ‘Brain-To-Vein,’ Point-Of-Care CAR-T Efforts In India

02 Jul 2025

• By Anju Ghangurde

From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.